ENSG00000291006 and ovarian cancer: Whereas the proliferation inhibition rate of ovarian cancer cells with cisplatin and 3-MA or niraparib and 3-MA combination treatment of ovarian cancer cells, the proliferation inhibition rate of ovarian cancer cells was significantly higher than that of the group treated with cisplatin or niraparib alone, and the difference in proliferation inhibition rate reduced by knockdown of LOC730101 was reverted (Fig. 6E).